Compare Corning Incorporated (GLW) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Corning (GLW) trades at $155.95, down 4.45% today amid a bearish technical outlook despite strong fundamentals. The company recently secured a significant $3B+ fiber supply agreement with AT&T, boosting its optical communications segment. GLW has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Analyst consensus remains positive with a $171.25 price target, though technical indicators show selling pressure with support at $149 and resistance at $158.

GLW presents a compelling long-term opportunity with strong revenue growth projections and strategic positioning in fiber optics for AI infrastructure. However, elevated valuation multiples (P/E 70.43) and ongoing patent litigation investigations pose near-term risks. The stock's current technical weakness may offer entry points for investors bullish on the company's fiber optic expansion and AI-driven connectivity demand.

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.